Latest Remuneration News

Ausgold Limited has promoted Ben Stockdale from CFO to CEO and appointed Reece Olney as GM Operations, reinforcing its leadership as the Katanning Gold Project approaches a final investment decision.

ASX has appointed Anthony Attia as its next Managing Director and CEO, bringing nearly 30 years of global exchange experience to guide the company through its ongoing transformation.

ReadCloud announces CEO Andrew Skelton’s departure after three years of operational overhaul and financial turnaround, appointing CFO Luke Murphy as interim CEO amid strong growth momentum.

Atlas Arteria reported a resilient 2025 with 9.3% EBITDA growth and steady toll revenue, while its Board unanimously urged investors to reject IFM’s unsolicited takeover offer, citing undervaluation and onerous conditions.

Ainsworth Game Technology has confirmed Ryan Comstock as CEO after six months as acting chief, tying his pay to company performance through incentive plans.

Pathkey.AI appoints Andrew Farnsworth as CEO, leveraging his defence and AI expertise to drive commercialisation of TrialKey and Chipforge platforms.

Besra Gold appoints Dr Raymond Shaw as CEO, leveraging his four decades of experience to steer the Bau Gold project through ongoing operational and strategic hurdles.

FleetPartners has reached an in-principle $27 million settlement to resolve a shareholder class action related to disclosures from 2017 to 2019, with the cost fully covered by insurance and no admission of liability.

Macquarie Bank Limited has posted a robust FY2026 result, with net profit attributable to ordinary equity holders soaring 74% to AUD 6.011 billion, underpinned by strong performances in its Banking and Financial Services and Commodities and Global Markets divisions.

Macquarie Group (ASX: MQG) reported a 30% jump in FY2026 net profit to A$4.85 billion, driven by growth across all divisions and bolstered by strategic investments in AI and sustainability. The board declared a total dividend of A$7 per share and maintained a strong capital position amid ongoing regulatory remediation.

Vectus Biosystems appoints Dr Tara Speranza as CEO and CTO to accelerate development of lead fibrosis drug VB0004 with performance-linked incentives.

Arovella Therapeutics has named Dr Nicole Van Der Weerden as acting CEO following Dr Michael Baker’s departure, positioning her to steer the company through the critical phase I trial of its CAR-iNKT therapy ALA-101.